Cancer Second Opinion
Second Opinions for Liver Cancer and HCC: Why China's Centres Change Management
Hepatocellular carcinoma (HCC) management is an area where Chinese specialist centres β led by Zhongshan Hospital Shanghai β consistently change treatment plans after second opinion review. The combination of world-leading HCC surgical volume, access to HAIC and TACE expertise unavailable outside Asia, and knowledge of China-approved systemic therapy combinations produces clinically significant discordance in a high proportion of referred cases.
Read guide